← CA FEED

Bristol Myers cancer drug meets main goal in late-stage study

Bristol Myers cancer drug meets main goal in late-stage study

AI BRIEFING

  • Bristol Myers' mezigdomide combination therapy meets goal in late-stage study
  • Combination therapy improved progression-free survival in patients with relapsed multiple myeloma
  • Bristol Myers' SUCCESSOR-2 trial shows promising results
ADVERTISEMENT
READ ORIGINAL ARTICLE